What to expect with
SUSVIMO® for DR

Explore the tabs below to learn about what to expect with SUSVIMO

Your consultation is an opportunity to discuss with your retina specialist how your current treatment fits into your schedule, and whether SUSVIMO may be the right fit for you.

  • You and your retina specialist will discuss your vision history

  • They will check that you’ve previously received at least two intravitreal eye injections of a vascular endothelial growth factor (VEGF) inhibitor that have worked for you

  • To support your conversation with your retina specialist, you can download our Doctor Conversation Guide here

After you and your retina specialist decide SUSVIMO is right for you, next steps could include:

  • Arranging for someone to bring you to and from your surgical procedure

  • Talking with your retina specialist about what to expect during, and after the procedure

Getting SUSVIMO is a short, one-time, outpatient procedure.

  • The procedure typically takes about 30 minutes

  • Your eye will be treated with local anesthesia to help you feel comfortable

  • Placing SUSVIMO requires only 1 small incision (3.5 mm)

  • SUSVIMO is placed underneath your eyelid, in the white part of your eye

  • You’ll be able to go home the same day

Your retina specialist will schedule follow-up appointments to check on your recovery and make sure your eye is healing properly.

  • Typically, people can return to most normal activities soon after the procedure

  • Do not participate in strenuous activities until 1 months after your implant procedure or after talking to your healthcare provider

  • For more information, you can download our Procedure Guide here


Positioning for your head

  • Keep your head above shoulder level for the rest of the day

  • Sleep with your head on 3 or more pillows if lying down during the day and night after your implant procedure


How to care for your eye

  • Do not remove the eye shield from your eye until you are told to by your healthcare provider. At bedtime, continue to wear an eye shield for at least 7 nights following your implant procedure

  • Take all post-operative eye medicines as your healthcare provider tells you to

  • Do not push on your eye, rub your eye, or touch the area of your eye where your implant is located (underneath your eyelid in the upper and outer part of your eye) for 30 days following your implant procedure

You and your retina specialist will schedule refill appointments every 9 months:*

  • The refill goes directly into your SUSVIMO implant

  • Follow the instructions provided by your retina specialist

  • Don’t push on your eye, rub your eye, or touch the area of your implant for 7 days after your refill - this is the area underneath your upper eyelid and outer part of your eye

  • Take antimicrobial eye drops as prescribed by your retina specialist

  • Notify your primary eye doctor or retina specialist immediately if you notice redness, sensitivity to light, pain, or a change in your vision. These are signs of an infection inside the eye called endophthalmitis

If your retina specialist determines that it is necessary, you may need an anti-VEGF injection in the gel-like part of the SUSVIMO-treated eye (intravitreal) before your next refill.

Your SUSVIMO Magnetic Resonance Imaging (MRI) implant card
Get your implant card from your healthcare provider after receiving SUSVIMO and keep the card in a safe place for future reference. This implant card contains important information about your SUSVIMO implant.

Show your current and future healthcare providers your implant card
This is important if you need to have an MRI. You may only receive an MRI under very specific conditions if you have the SUSVIMO implant. Your healthcare provider will review the information on your implant card and will let you know if you should receive an MRI.

There is more to know about preparation and post-procedure care for the implant procedure and refills, refer to the Medication Guide (the section titled "How will I receive SUSVIMO?") for important instructions.

When to consult your retina specialist

Seek immediate care from your retina specialist if there are:

  • Sudden changes in your vision (an increase in moving spots, the appearance of “spider webs”, flashing lights, or a loss in vision)

  • Increasing eye pain

  • Progressive vision loss

  • Sensitivity to light

  • Increasing redness in the white of the eye

  • A sudden sensation that something is in your eye

  • Eye discharge or watering

"My retina specialist explained SUSVIMO is an implant, the size of a grain of rice, that continuously releases medicine."

Dawn
SUSVIMO patient

Patient has been compensated by Genentech. Patient experiences may vary.

Please see the video for more information about side effects, including the risk of endophthalmitis.

vector orange line right hand rail CTA box

YOUR DOCTOR CONVERSATION GUIDE

Answer a few questions to get your personalized conversation guide. Ask your retina specialist if SUSVIMO is right for you.

Important Safety Information

What is SUSVIMO® (ranibizumab injection)?

SUSVIMO (ranibizumab injection) is a prescription medicine used to treat adults with neovascular (wet) Age‑related Macular Degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR) who have responded to at least two injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal).
 

It is not known if SUSVIMO is safe and effective in children.

What is the most important information I should know about SUSVIMO?

SUSVIMO (ranibizumab injection) is delivered into the eye using the SUSVIMO implant. The SUSVIMO implant and the procedures to insert, fill, refill, and remove the eye (ocular) implant can cause serious side effects, including:

  • An eye infection (endophthalmitis). Endophthalmitis is an infection of the eyeball that can cause permanent damage to your eye, including blindness. Call your healthcare provider right away if you have increasing eye pain, vision loss, sensitivity to light, or redness in the white of the eye. Endophthalmitis requires urgent (same-day) medical or surgical treatment
  • A missing layer on top of the white part of the eye (conjunctival erosion). Conjunctival erosion is an area that becomes missing (defect) in the layer (conjunctiva) that covers the white part of the eye, which may result in exposure of the implant. Call your healthcare provider right away if you have a sudden feeling that something is in your eye (foreign body sensation), if you have eye discharge, or watering of the eye. Conjunctival erosion may require surgical treatment
  • An opening of the layer that covers the white part of the eye (conjunctival retraction). Conjunctival retraction is an opening or gaping in the layer (conjunctiva) that covers the white part of the eye, which may cause the implant to be exposed. Call your healthcare provider right away if you have a sudden feeling that something is in your eye (foreign body sensation), if you have eye discharge, or watering of the eye. Conjunctival retraction may require surgical treatment
     

Do not receive SUSVIMO if you:

  • Have an infection in or around your eye
  • Have active swelling around your eye that may include pain and redness
  • Are allergic to ranibizumab or any of the ingredients in SUSVIMO

Talk to your healthcare provider before receiving SUSVIMO if you have any of these conditions.
 

Before receiving SUSVIMO, tell your healthcare provider about all of your medical conditions, including if you:

  • Are currently taking or have recently taken medicines that lower the chance of blood clots forming in the body, such as warfarin, low or regular doses of aspirin, or nonsteroidal anti-inflammatory drugs (such as ibuprofen)
  • Are pregnant or plan to become pregnant. It is not known if SUSVIMO will harm your unborn baby. You should use birth control during your treatment with SUSVIMO and for 12 months after your last dose of SUSVIMO
  • Are breastfeeding or plan to breastfeed. It is not known if SUSVIMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive SUSVIMO

Tell your healthcare provider about all the medicines you take, including prescription and over‑the‑counter medicines, vitamins, and herbal supplements.
 

What are other possible side effects of SUSVIMO?
The SUSVIMO implant and the procedures to insert, fill, refill, and remove the eye (ocular) implant can cause other serious side effects, including:

  • Tear and separation of layers of the retina (rhegmatogenous retinal detachment): This is a tear and separation of one of the layers of the retina in the back of the eye that senses light. Call your healthcare provider or go to the emergency room right away if you see flashing lights, see a curtain or veil covering part of your vision, or have a change in, or a loss of vision. Rhegmatogenous retinal detachment requires surgical treatment
  • Implant movement (implant dislocation): Tell your healthcare provider right away if you notice that the implant has moved out of place. This movement may require surgical treatment to correct
  • Implant damage: Damage to the implant that prevents continued treatment (refills) with SUSVIMO. If the implant is not able to be properly refilled, your wet AMD or DME may be inadequately treated and your physician may remove the implant and/or change your treatment
  • Bleeding (vitreous hemorrhage): Vitreous hemorrhage is bleeding within the gel-like substance (vitreous) inside of your eye. Call your healthcare provider right away if you have an increase in moving spots or what looks like spider webs in your vision, as you may need an additional eye surgery
  • Bump on top of the white layer of the eye (conjunctival bleb): conjunctival bleb is a small bulge in the layer (conjunctiva) that covers the white part of the eye where the implant is inserted. This may be due to leakage of fluid from the inside of the eye. Call your healthcare provider right away if you have a sudden feeling that something is in your eye (foreign body sensation), see a bulge over the white part of your eye, if you have eye discharge, or watering of the eye. You may need medical or surgical treatment
  • Temporary decrease in vision after the SUSVIMO procedure
     

What are the most common side effects of SUSVIMO?

  • Blood on the white of the eye
  • Eye pain
  • Redness in the white of the eye
  • Sensitivity to light

These are not all the possible side effects of SUSVIMO.
 

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.

Please see Important Safety Information, including Serious Side Effects, as well as the SUSVIMO full Prescribing Information and Medication Guide.

    • SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.

      SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.

    • Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.

      Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.

    • SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.

      SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.

    • Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.

      Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.

    • Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.

      Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.

    • Data on file. Genentech, Inc. 2021.

      Data on file. Genentech, Inc. 2021.

    • Data on file. Genentech, Inc. 2021.

      Data on file. Genentech, Inc. 2021.

    • Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.

      Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.

    • A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934

      A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934

    • Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.

      Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.

    • Data on file. Genentech, Inc. 2021.

      Data on file. Genentech, Inc. 2021.

    • Data on file. Genentech, Inc. 2021.

      Data on file. Genentech, Inc. 2021.

    • Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.

      Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.

    +